Secretagogin may not be a new neuroendocrine biomarker in schizophrenia while levels may reflect clinical severity

References

• Albus M. Clinical courses of schizophrenia. Pharmacopsychiatry. 2012;45(Suppl 1):S31–S35.
   PubMedGoogle Scholar
• Steiner J, Guest PC, Rahmoune H, et al. The application of multiplex biomarker techniques for improved stratification and treatment of schizophrenia patients. Methods Mol Biol. 2017;1546:19–35. doi: 10.1007/978-1-4939-6730-8_2
   Google Scholar
• Gartner W, Lang W, Leutmetzer F, et al. Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2+)-binding protein. Cereb Cortex. 2001;11:1161–1169. doi: 10.1093/cercor/11.12.1161
   PubMed Web of Science ®Google Scholar
• Wagner L, Oliyarnyk O, Gartner W, et al. Cloning and expression of secretagogin, a novel neuroendocrine- and pancreatic islet of Langerhans-specific Ca2+-binding protein. J Biol Chem. 2000;275:24740–24751. doi: 10.1074/jbc.M001974200
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Wakino S, Kimoto M, et al. The hydrolase DDAH2 enhances pancreatic insulin secretion by transcriptional regulation of secretagogin through a Sirt1-dependent mechanism in mice. FASEB J. 2013;27:2301–2315. doi: 10.1096/fj.12-226092
   PubMed Web of Science ®Google Scholar
• Bai Y, Sun Y, Peng J, et al. Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494. Oncotarget. 2014;5:7760–7775. doi: 10.18632/oncotarget.2305
   Google Scholar
• Maj M, Milenkovic I, Bauer J, et al. Novel insights into the distribution and functional aspects of the calcium binding protein secretagogin from studies on rat brain and primary neuronal cell culture. Front Mol Neurosci [Internet]. 2012 [cited 2019 Feb 16];5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412267/.
   Google Scholar
• Raju CS, Spatazza J, Stanco A, et al. Secretagogin is expressed by developing neocortical GABAergic neurons in humans but not mice and increases neurite arbor size and complexity. Cereb Cortex. 2018;28:1946–1958. doi: 10.1093/cercor/bhx101
   Web of Science ®Google Scholar
• Fung SJ, Webster MJ, Sivagnanasundaram S, et al. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry. 2010;167:1479–1488. doi: 10.1176/appi.ajp.2010.09060784
   PubMed Web of Science ®Google Scholar
• Glausier JR, Fish KN, Lewis DA. Altered parvalbumin basket cell inputs in the dorsolateral prefrontal cortex of schizophrenia subjects. Mol Psychiatry. 2014;19:30–36. doi: 10.1038/mp.2013.152
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 2003;23:6315–6326. doi: 10.1523/JNEUROSCI.23-15-06315.2003
   PubMed Web of Science ®Google Scholar
• Mellios N, Huang H-S, Baker SP, et al. Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry. 2009;65:1006–1014. doi: 10.1016/j.biopsych.2008.11.019
   PubMed Web of Science ®Google Scholar
• Morris HM, Hashimoto T, Lewis DA. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb Cortex. 2008;18:1575–1587. doi: 10.1093/cercor/bhm186
   PubMed Web of Science ®Google Scholar
• Volk DW, Matsubara T, Li S, et al. Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia. Am J Psychiatry. 2012;169:1082–1091. doi: 10.1176/appi.ajp.2012.12030305
   PubMed Web of Science ®Google Scholar
• Wang DD, Kriegstein AR. Defining the role of GABA in cortical development. J Physiol (Lond). 2009;587:1873–1879. doi: 10.1113/jphysiol.2008.167635
   Google Scholar
• Attems J, Preusser M, Grosinger-Quass M, et al. Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer’s disease. Neuropathol Appl Neurobiol. 2008;34:23–32.
   PubMed Web of Science ®Google Scholar
• Attems J, Ittner A, Jellinger K, et al. Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice. J Neural Transm (Vienna). 2011;118:737–745. doi: 10.1007/s00702-011-0626-5
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276. doi: 10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988;23:99–110. doi: 10.1016/0165-1781(88)90038-8
   PubMed Web of Science ®Google Scholar
• Kay SR. Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison. Psychiatr Q. 1990;61:163–178. doi: 10.1007/BF01064966
   PubMedGoogle Scholar
• Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull. 1990;16:537–545. doi: 10.1093/schbul/16.3.537
   PubMed Web of Science ®Google Scholar
• Kay SR, Sandyk R. Experimental models of schizophrenia. Int J Neurosci. 1991;58:69–82. doi: 10.3109/00207459108987184
   PubMed Web of Science ®Google Scholar
• Kostakoğlu AE, Batur S, Tiryaki A, et al. Pozitif ve negatif sendrom ölçeğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi. 1999;14(44):23–32.
   Web of Science ®Google Scholar
• Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents: comparing apples and oranges! Indian J Psychiatry. 2013;55:207–208. doi: 10.4103/0019-5545.105522
   PubMed Web of Science ®Google Scholar
• Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. New York: John Wiley & Sons; 2018.
   Google Scholar
• Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663–667. doi: 10.4088/JCP.v64n0607
   PubMed Web of Science ®Google Scholar
• Krishnamurthy D, Harris LW, Levin Y, et al. Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J Biol Psychiatry. 2013;14:478–489. doi: 10.3109/15622975.2011.601759
   Web of Science ®Google Scholar
• Alhowikan AM, Ayadhi LA, Halepoto DM. Secretagogin (SCGN) plasma levels and their association with cognitive and social behavior in children with autism spectrum disorder ASD). J Coll Physici. 2017;27:222–226.
   Google Scholar
• Yang S-Y, Lee J-J, Lee J-H, et al. Secretagogin affects insulin secretion in pancreatic β-cells by regulating actin dynamics and focal adhesion. Biochem J. 2016;473:1791–1803. doi: 10.1042/BCJ20160137
   Web of Science ®Google Scholar
• Alpár A, Attems J, Mulder J, et al. The renaissance of Ca2+-binding proteins in the nervous system: secretagogin takes center stage. Cell Signal. 2012;24:378–387. doi: 10.1016/j.cellsig.2011.09.028
   Web of Science ®Google Scholar